Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABY-025
- Development stage
- Unknown
- Lead developer
- Affibody
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ABY-025 is a small engineered Affibody molecule (approximately 7–7.6 kDa) that specifically targets the human epidermal growth factor receptor type 2 (HER2). It is used as a diagnostic radiopharmaceutical for noninvasive imaging of HER2 expression in tumors using PET or SPECT modalities when labeled with isotopes such as gallium Ga 68 or indium In 111. Upon intravenous administration, radiolabeled ABY-025 binds with high affinity to HER2-expressing tumor cells, enabling detection and quantification of HER2 status in cancers such as metastatic breast cancer and gastroesophageal junction cancer. This facilitates patient stratification for HER2-targeted therapies and assessment of therapeutic response. The molecule was developed by protein engineering to improve its biochemical properties and minimize immunogenicity[1][5][8].
- Other names
- gallium Ga 68-labeled affibody ABY-025111In-ABY-025[68Ga]Ga-ABY-025GE-226GE226GE 226
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ABY-025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABY-025.